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Nano- and micro-particulate carriers enable the site-specific delivery for controlled biological responses and can 
harness the intrinsic pathways by which the body responds to natural invaders. These particles are in the size 
range which naturally associates with many innate immune cells, including antigen presenting cells (APCs). 
Through controlled design properties, engineered nano- and microparticle drug delivery vehicles have the 
potential to expand the breadth of many therapeutic approaches, impacting immunological outcomes through 
cell-specific targeted delivery. However, in many applications, such as mucosal vaccines or controlled-release 
lung depots, optimal particle properties have not yet been identified. Physical properties such as size, shape, 
and surface chemistry are known to impact cellular interactions, particle margination, and biodistribution; as 
such, many particle design considerations have been established for systemic intravenous (IV) administration to 
create long-circulating drug delivery vehicles  [3]. However, much less is known about particle design 
parameters which are critical to interfacing with and directing the immune system, especially through non-IV 
administration. 
To this end, recent work has investigated the role of surface charge and functionality on pulmonary drug delivery 
carriers, as potential vaccine formulations or immune modulators. These results find that positively charged 
nanoparticle vaccine formulations induce robust antigen-specific mucosal and systemic antibody responses 
following pulmonary administration, whereas negatively charged nanoparticles fail to do so. Cationic 
nanoparticles were shown to produce superior antigen-specific IgG and IgA responses, as well as the 
upregulation of various co-stimulatory molecules, enhanced germinal center B cell formation, and CD4+ T cell 
activation, when compared to otherwise equivalent anionic particles [4]. In combination, these indicate that 
cationic particles by themselves provide an adjuvant-like effect when delivered to the airways. Adjuvants are 
molecules which enhance immune responses by stimulating various cellular pathways and are critical 
components of vaccine formulations [6]. These cationic particles showed increased association with pulmonary 
APCs following lung administration, including preferential association with lung dendritic cell populations, 
producing increased cytokine and chemokines in the lung [5]. Thus, cationic.  
While cationic nanoparticles themselves can act as adjuvants, 
these responses can be enhanced by incorporating  toll-like-
receptor (TLR) ligands to the particle surface [7]. In this work, we 
have engineered a series of particles to investigate the role of 
adjuvant density on the particle. We incorporate two TLR 
adjuvant molecules, CpG and LPS, on the surface of both 
cationic and anionic particle carriers and quantify the immune 
response in various biological environments as a function of 
particle characteristics. As with unmodified particles, cationic 
formulations produce more robust responses than anionic 
formulations. Furthermore, our results indicate that when dosed 
at equivalent particle concentrations with varied adjuvant surface 
densities, particles with the highest adjuvant density per particle 
produce the largest in vitro stimulation; however, when dosed at 
equivalent adjuvant mass per sample, particles of the lowest 
adjuvant density, corresponding to the highest number of 
particles dosed, resulted in superior stimulation. These results 
indicate a trade-off between adjuvant density and particle 
number. Overall, we believe this work provides a set of design 
rules which inform particulate vaccine formulations, to ensure both potency and safety, with potential future 
applications for novel treatments for cancer, inflammation, and allergy. 
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Figure 1. IL-6 production from bone marrow 
macrophages (BMMs) incubated with LPS-
particles for 24 hrs. B, C & D represent three 
anionic 500 nm LPS-adjuvant particles with 
decreasing amounts of LPS. The left graph 
shows dosing at equivalent particle 
concentration; the right graph shows dosing 
at equivalent LPS concentration. 
 
